Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: CTSG

Gene summary for CTSG

Gene summary.

Gene information	Species	Human
	Gene symbol	CTSG
	Gene ID	1511
	Gene name	cathepsin G
	Gene Alias	CATG
	Cytomap	14q12
	Gene Type	protein-coding
	GO ID	GO:0001906
	UniProtAcc	P08311

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
1511	CTSG	C08	Human	Oral cavity	OSCC	1.34e-11	-3.35e-02	0.1919
1511	CTSG	EOLP-1	Human	Oral cavity	EOLP	1.85e-18	1.03e+00	-0.0202
1511	CTSG	EOLP-2	Human	Oral cavity	EOLP	2.90e-18	8.33e-01	-0.0203
1511	CTSG	NEOLP-1	Human	Oral cavity	NEOLP	9.16e-08	6.75e-01	-0.0194

Page: 1

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:002241119	Oral cavity	OSCC	cellular component disassembly	283/7305	443/18723	9.57e-27	3.37e-24	283
GO:004440320	Oral cavity	OSCC	biological process involved in symbiotic interaction	173/7305	290/18723	6.80e-13	3.19e-11	173
GO:005160410	Oral cavity	OSCC	protein maturation	170/7305	294/18723	3.97e-11	1.28e-09	170
GO:003249617	Oral cavity	OSCC	response to lipopolysaccharide	178/7305	343/18723	7.27e-07	1.03e-05	178
GO:00164856	Oral cavity	OSCC	protein processing	121/7305	225/18723	4.56e-06	5.23e-05	121
GO:007121615	Oral cavity	OSCC	cellular response to biotic stimulus	129/7305	246/18723	1.20e-05	1.23e-04	129
GO:000223717	Oral cavity	OSCC	response to molecule of bacterial origin	181/7305	363/18723	1.48e-05	1.49e-04	181
GO:007122210	Oral cavity	OSCC	cellular response to lipopolysaccharide	110/7305	209/18723	4.15e-05	3.60e-04	110
GO:00192214	Oral cavity	OSCC	cytokine-mediated signaling pathway	222/7305	472/18723	2.02e-04	1.35e-03	222
GO:00517029	Oral cavity	OSCC	biological process involved in interaction with symbiont	54/7305	94/18723	2.20e-04	1.44e-03	54
GO:007121910	Oral cavity	OSCC	cellular response to molecule of bacterial origin	112/7305	221/18723	2.64e-04	1.69e-03	112
GO:00301983	Oral cavity	OSCC	extracellular matrix organization	146/7305	301/18723	4.67e-04	2.77e-03	146
GO:00452293	Oral cavity	OSCC	external encapsulating structure organization	147/7305	304/18723	5.30e-04	3.08e-03	147
GO:00430623	Oral cavity	OSCC	extracellular structure organization	146/7305	302/18723	5.59e-04	3.23e-03	146
GO:00226171	Oral cavity	OSCC	extracellular matrix disassembly	37/7305	63/18723	1.18e-03	5.99e-03	37
GO:00024441	Oral cavity	OSCC	myeloid leukocyte mediated immunity	50/7305	99/18723	1.31e-02	4.34e-02	50
GO:002241121	Oral cavity	EOLP	cellular component disassembly	94/2218	443/18723	1.00e-08	4.89e-07	94
GO:001922112	Oral cavity	EOLP	cytokine-mediated signaling pathway	94/2218	472/18723	2.36e-07	7.37e-06	94
GO:004440325	Oral cavity	EOLP	biological process involved in symbiotic interaction	57/2218	290/18723	7.75e-05	9.39e-04	57
GO:003249623	Oral cavity	EOLP	response to lipopolysaccharide	65/2218	343/18723	8.02e-05	9.65e-04	65

Page: 1 2 3

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0514623	Oral cavity	EOLP	Amoebiasis	26/1218	102/8465	2.09e-03	7.03e-03	4.15e-03	26
hsa0514633	Oral cavity	EOLP	Amoebiasis	26/1218	102/8465	2.09e-03	7.03e-03	4.15e-03	26
hsa0514641	Oral cavity	NEOLP	Amoebiasis	26/1112	102/8465	5.36e-04	3.05e-03	1.92e-03	26
hsa0514651	Oral cavity	NEOLP	Amoebiasis	26/1112	102/8465	5.36e-04	3.05e-03	1.92e-03	26

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand	Receptor	LRpair	Pathway	Tissue	Disease Stage
CTSG	F2RL3	CTSG_F2RL3	PARs	Breast	Healthy
CTSG	F2R	CTSG_F2R	PARs	Cervix	ADJ
CTSG	F2R	CTSG_F2R	PARs	Cervix	CC
CTSG	PARD3	CTSG_PARD3	PARs	Cervix	CC
CTSG	F2R	CTSG_F2R	PARs	Cervix	Precancer
CTSG	F2R	CTSG_F2R	PARs	CRC	AD
CTSG	F2RL3	CTSG_F2RL3	PARs	CRC	AD
CTSG	PARD3	CTSG_PARD3	PARs	CRC	AD
CTSG	PARD3	CTSG_PARD3	PARs	CRC	ADJ
CTSG	F2R	CTSG_F2R	PARs	CRC	SER
CTSG	PARD3	CTSG_PARD3	PARs	CRC	SER
CTSG	PARD3	CTSG_PARD3	PARs	Endometrium	ADJ
CTSG	F2R	CTSG_F2R	PARs	Endometrium	AEH
CTSG	PARD3	CTSG_PARD3	PARs	Endometrium	AEH
CTSG	F2R	CTSG_F2R	PARs	Esophagus	Healthy
CTSG	F2RL1	CTSG_F2RL1	PARs	GC	Healthy
CTSG	F2R	CTSG_F2R	PARs	HNSCC	ADJ
CTSG	PARD3	CTSG_PARD3	PARs	HNSCC	ADJ
CTSG	F2R	CTSG_F2R	PARs	HNSCC	Healthy
CTSG	F2R	CTSG_F2R	PARs	HNSCC	OSCC

Page: 1 2

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

CTSG

SNV

Missense_Mutation

c.352N>T

p.Val118Phe

p.V118F

P08311

protein_coding

deleterious(0)

possibly_damaging(0.775)

TCGA-A8-A06X-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

CTSG

SNV

Missense_Mutation

novel

c.94N>A

p.Arg32Ser

p.R32S

P08311

protein_coding

deleterious(0.02)

probably_damaging(0.912)

TCGA-GI-A2C8-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unspecific

Adriamycin

CTSG

insertion

In_Frame_Ins

novel

c.100_101insTTCTCTCTCTCTCTCTCTCACACACACACACAC

p.Tyr34delinsPheLeuSerLeuSerLeuSerHisThrHisThrHis

p.Y34delinsFLSLSLSHTHTH

P08311

protein_coding

TCGA-A2-A0CU-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

tamoxiphen

CTSG

insertion

Nonsense_Mutation

novel

c.532_533insAGGGAAAC

p.Ser178Ter

p.S178*

P08311

protein_coding

TCGA-AQ-A04J-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

CTSG

insertion

Frame_Shift_Ins

novel

c.531_532insCTGGGAAACA

p.Ser178LeufsTer34

p.S178Lfs*34

P08311

protein_coding

TCGA-AQ-A04J-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

CTSG

SNV

Missense_Mutation

c.73C>T

p.Arg25Trp

p.R25W

P08311

protein_coding

deleterious(0.04)

possibly_damaging(0.865)

TCGA-EK-A2RK-01

Cervix

cervical & endocervical cancer

Female

>=65

I/II

Unknown

CTSG

SNV

Missense_Mutation

rs865944750

c.545N>A

p.Arg182Gln

p.R182Q

P08311

protein_coding

tolerated(0.43)

benign(0)

TCGA-AA-A01R-01

Colorectum

colon adenocarcinoma

Male

<65

III/IV

Chemotherapy

5-fluorouracil

CTSG

SNV

Missense_Mutation

novel

c.155T>G

p.Phe52Cys

p.F52C

P08311

protein_coding

deleterious(0.01)

probably_damaging(0.998)

TCGA-CA-6717-01

Colorectum

colon adenocarcinoma

Male

<65

I/II

Chemotherapy

oxaliplatin

CTSG

SNV

Missense_Mutation

c.643G>A

p.Val215Ile

p.V215I

P08311

protein_coding

deleterious(0.03)

possibly_damaging(0.543)

TCGA-A5-A0VP-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

CTSG

SNV

Missense_Mutation

novel

c.109T>C

p.Tyr37His

p.Y37H

P08311

protein_coding

deleterious(0.05)

possibly_damaging(0.57)

TCGA-AP-A051-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3 4

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
1511	CTSG	DRUGGABLE GENOME, PROTEASE, ENZYME, CELL SURFACE		JNJ-10311795	CHEMBL374027
1511	CTSG	DRUGGABLE GENOME, PROTEASE, ENZYME, CELL SURFACE		SULFONE		9125494
1511	CTSG	DRUGGABLE GENOME, PROTEASE, ENZYME, CELL SURFACE		IFN		11352647
1511	CTSG	DRUGGABLE GENOME, PROTEASE, ENZYME, CELL SURFACE		DERMOLASTIN
1511	CTSG	DRUGGABLE GENOME, PROTEASE, ENZYME, CELL SURFACE	inhibitor	252166826
1511	CTSG	DRUGGABLE GENOME, PROTEASE, ENZYME, CELL SURFACE		Peptide analog 57
1511	CTSG	DRUGGABLE GENOME, PROTEASE, ENZYME, CELL SURFACE		Peptide analog 58
1511	CTSG	DRUGGABLE GENOME, PROTEASE, ENZYME, CELL SURFACE		LAK		2007574
1511	CTSG	DRUGGABLE GENOME, PROTEASE, ENZYME, CELL SURFACE		Peptide analog 60
1511	CTSG	DRUGGABLE GENOME, PROTEASE, ENZYME, CELL SURFACE		Peptide analog 59

Page: 1 2 3